Khosla Ventures
Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. It provides capital and strategic guidance to startups across stages, focusing on technology-driven companies in areas such as artificial intelligence, climate and sustainability, enterprise software and services, fintech, digital health, medical technology and diagnostics, therapeutics, consumer products, and frontier technologies. The firm backs bold ventures with the potential to disrupt markets and improve lives, supporting companies from early to growth stages and working closely with entrepreneurs to apply science, technology and innovative business models. While primarily investing in North American technology companies, Khosla Ventures pursues opportunities globally and emphasizes experimentation and impact alongside financial returns. The firm also maintains related impact initiatives that support entrepreneurs addressing socio-economic challenges in emerging markets.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Biotechnology
Overture Life
Venture Round in 2025
Overture Life, Inc. is a biotechnology company based in New York, established in 2017, that specializes in developing robotic solutions for in vitro fertilization (IVF) applications. The company focuses on automating the IVF process through innovative medical devices and embryo testing methodologies, which enhance the efficiency and success rates of fertility treatments. By optimizing resource use and lowering costs, Overture Life aims to make IVF more accessible to a broader audience. Its technology includes automated cryopreservation and embryo testing services, enabling fertility clinics to identify viable embryos prior to implantation, thereby improving patient outcomes and supporting individuals in their journey to parenthood.
Science
Convertible Note in 2025
Science is a startup company that develops technologies for a range of serious unmet medical needs.
Tempero Bio
Series B in 2025
Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for substance use disorders. Its primary focus is on creating transformative therapies, including an orally available metabotropic glutamate receptor (mGluR5) negative allosteric modulator (NAM), designed to regulate neural signaling and treat conditions such as cocaine and alcohol use disorders.
Resource Chemical
Venture Round in 2025
ReSource Chemical is a company based in Berkeley, California, focused on developing high-performance plastics derived from carbon dioxide. The company utilizes a proprietary bio-based platform to create chemicals that enable the production of environmentally friendly plastics with superior physical properties compared to traditional fossil fuel-based plastics. By converting CO2 into these innovative materials, ReSource Chemical aims to provide sustainable alternatives that do not contribute to environmental pollution.
Clear Labs
Series D in 2025
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Enzymit
Series A in 2024
Enzymit is a biotechnology company focused on revolutionizing global manufacturing through sustainable and efficient bio-production methods. It specializes in developing cell-free bio-production technology that aims to eliminate the inefficiencies and complexities associated with traditional bio-production. Enzymit employs artificial intelligence and deep learning algorithms to design novel enzymes, which serve as molecular machines capable of transforming abundant feedstocks into valuable products, including pharmaceuticals, cosmetics, food, and materials. The company’s small, modular bio-reactors facilitate this process, promoting resource independence while minimizing environmental impact. By moving away from conventional whole-cell methods to utilizing nature's elemental building blocks, Enzymit enhances cost-effectiveness, efficiency, and sustainability in bio-production, while also providing greater flexibility in product customization for various industries.
Synex Medical
Series A in 2024
Synex Medical is a company focused on advancing health monitoring technology through non-invasive blood testing. It has developed a portable device that utilizes a miniaturized magnetic resonance system to measure blood metabolites without the need for skin penetration. This innovative approach employs only magnets and radio waves, ensuring no adverse health effects for users. By accurately measuring critical metabolites such as glucose, lactate, and ketones, Synex Medical's technology empowers individuals to monitor their health proactively and make informed decisions about their well-being.
Inflammatix
Series E in 2024
Inflammatix develops rapid molecular diagnostics tests that interpret the immune system to resolve major clinical challenges. Initially focused on acute bacterial and viral infections, sepsis, and other conditions like tropical infections and autoimmune diseases.
Viome Life Sciences
Series D in 2024
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Egenesis
Series D in 2024
Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.
Noetik
Series A in 2024
Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By harnessing self-supervised learning and integrating diverse human multimodal data, the company aims to enhance the precision and effectiveness of immunotherapies. This approach enables the development of more personalized cancer treatments, contributing to the advancement of targeted therapies in oncology.
Openwater
Venture Round in 2024
Openwater is a medical technology startup founded in 2016 and based in San Francisco, California. The company specializes in developing advanced wearable devices that utilize novel optoelectronics to achieve MRI-like resolution for medical diagnostics and treatments. By employing LCDs with small pixels, Openwater's technology creates holographic images that reduce scattering, enabling physicians to visualize the inner workings of the body and brain at a cellular level. This innovation allows for precise diagnosis and targeted treatment of diseases by manipulating or destroying individual cells without damaging surrounding tissue. Openwater aims to revolutionize medical imaging and improve patient outcomes through its cutting-edge approach.
Q Bio
Venture Round in 2024
Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.
Karius
Series C in 2024
Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.
Yoneda Labs
Seed Round in 2024
Yoneda Labs is a developer of AI-based software designed to assist chemists in optimizing reaction parameters essential for the synthesis of drugs and materials. The platform enables users to determine critical factors such as temperature, concentration, and catalyst, thereby enhancing the efficiency and speed of chemical laboratory processes. By leveraging advanced artificial intelligence, Yoneda Labs aims to streamline the development of chemical reactions, ultimately facilitating faster innovation in the pharmaceutical and material sciences industries.
Rubedo Life Sciences
Series A in 2024
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.
Nabla Bio
Series A in 2024
Nabla Bio is a biotechnology company that uses artificial intelligence and lab technologies to rationally design novel proteins for drug development. They aim to create medicines and improve nutrition by engineering proteins with enhanced qualities.
Loyal
Series B in 2024
Loyal is a biotechnology company focused on developing medicines to extend the lifespan of dogs. By creating drugs that potentially slow aging processes, they aim to delay or prevent age-related diseases such as cancer and dementia.
Relation Therapeutics
Seed Round in 2024
Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.
Siolta Therapeutics
Series C in 2024
Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.
Moonwalk Biosciences
Series A in 2024
Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company specializes in creating a profiling and engineering technology platform that leverages advanced artificial intelligence predictions to offer a comprehensive view of the epigenome in both health and disease states. This innovative approach aims to revolutionize therapy discovery and development, enabling healthcare providers to reprogram cells back to their healthy state.
Encellin
Series A in 2023
Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.
Eligo Bioscience
Series B in 2023
Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.
Vivodyne
Seed Round in 2023
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies. Its platform cultures human tissues in labs for realistic preclinical drug testing, using advanced AI to accelerate the creation of safe and effective therapeutics.
CellFE
Series A in 2023
CellFE Inc. is a biotechnology company based in San Carlos, California, established in 2017. It specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. This innovative platform enhances the manufacturing and development of cell therapies by utilizing rapid cell compression techniques that facilitate the uptake of therapeutic molecules from surrounding fluids. By enabling the transport of hard-to-deliver molecules, CellFE aims to improve the effectiveness of treatments for various disorders, supporting medical researchers in their efforts to advance patient care and outcomes.
Rejuvenation Technologies
Seed Round in 2023
Founded in 2016, Rejuvenation Technologies is a biotechnology company based in Mountain View, California. It specializes in developing nucleoside-modified TERT mRNA to safely extend telomeres for human health extension.
Viome Life Sciences
Series C in 2023
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
SiPhox Health
Seed Round in 2023
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.
Surge Therapeutics
Series B in 2023
SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.
SiPhox Health
Series A in 2023
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.
Ceibo
Series B in 2023
Ceibo specializes in proprietary technologies for efficient copper sulphide leaching and dust suppression in mining operations. Currently active in several major mining assets worldwide.
Tachyon Therapeutics
Series A in 2023
Tachyon Therapeutics develops innovative compounds to enhance cancer treatments. It is currently conducting Phase 1 clinical trials to evaluate the safety and efficacy of its lead compound, TACH101.
IgGenix
Series B in 2023
IgGenix is a biotechnology company that develops an antibody-based therapeutic platform to treat food and other severe allergies. The platform re-engineers allergen-specific IgE antibodies into IgG antibodies to suppress the allergic cascade and alleviate or prevent allergic reactions. It identifies rare human B cells expressing allergen-binding antibodies and engineers them to endow immune-modulating activities derived from the IgG antibody class. Based in South San Francisco, California, the company aims to accelerate clinical responses to life-threatening allergies.
Synchron
Series C in 2022
Synchron is a company that develops implantable neural interfaces designed to restore motor function by recording and interpreting brain activity through minimally invasive devices. Its catheter-delivered brain implants record neuron signals and translate them into control signals for prosthetics or digital devices, enabling users with motor impairments to interact with technology through thought. The devices incorporate electrode arrays within a stent-like platform to create a brain-computer interface that modulates neural activity in targeted brain regions. The goal is to provide a less invasive option for patients to regain voluntary control over assistive technologies, augmenting mobility and communication for those with paralysis or severe motor limitation.
Bionaut Labs
Series B in 2022
Founded in 2016, Bionaut Labs specializes in developing intra-tissue navigation platforms using micro-robots for precise anatomical targeting. Its innovative technology enables remote-controlled delivery of therapeutics to challenging clinical settings, revolutionizing the treatment of central nervous system disorders and other diseases.
Surge Therapeutics
Series A in 2022
SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.
Viome Life Sciences
Series C in 2022
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Ochre Bio
Series A in 2022
Ochre Bio is a biotechnology company founded in 2019 and headquartered in Oxford, United Kingdom. The firm focuses on developing genomic medicines that rejuvenate donor livers before transplantation, aiming to expand the supply of healthy organs for patients. By using genomics to identify and silence over‑active genes that drive liver disease, Ochre Bio tests novel RNA‑based therapies directly in discarded donor livers maintained on machine‑based perfusion systems. This approach allows the company to evaluate treatments in a human organ context, reducing complications such as cirrhosis and improving transplant outcomes. With more than fifteen years of liver genomics research experience, Ochre Bio leverages deep phenotyping and advanced therapeutic modalities to create a pipeline of medicines for liver and liver‑mediated conditions.
Equii
Seed Round in 2022
Equii is a food technology company that discovers nutritious microbial proteins from various sources. These are used to ferment grains, resulting in high-protein grain flours.
Carver Biosciences
Seed Round in 2022
Carver Biosciences is a biotechnology company developing antiviral therapies that target RNA viruses, including CRISPR/Cas13-based approaches. Its work centers on RNA-level interventions designed to destroy respiratory viruses and prevent their replication, with the aim of providing therapeutics that complement vaccination and other antiviral measures. The company seeks to arrest the progression of infection and offer ready alternative treatments for patients facing RNA virus–related diseases.
Arpeggio Bio
Series A in 2022
Arpeggio Bio, established in 2017 and headquartered in Boulder, Colorado, specializes in developing innovative software that captures snapshots of cellular RNA activity. By combining biological assays with advanced machine learning algorithms, the company enables pharmaceutical and biotechnology firms to understand a drug's mechanism of action at low sequencing depths. Arpeggio Bio's technology reveals intricate biological networks, facilitating more informed therapeutic development.
Prellis Biologics
Series C in 2022
Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.
Genecis
Series A in 2022
Genecis is an early-stage organic waste processing startup that uses biotechnology to convert waste into biodegradable plastics and other high-value materials. It converts organic waste into PHA (Polyhydroxyalkanoate), a biodegradable, compostable, and non-toxic polymer that can be tuned to replace a wide variety of traditional plastics. PHA can be used for single-use plastics, clothing and textiles, automotive interiors, medical tools and products, and food contact applications.
Faeth Therapeutics
Series A in 2022
Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.
CHARM Therapeutics
Series A in 2022
CHARM Therapeutics uses 3D deep learning and advanced drug discovery technologies to develop transformational medicines for diseases that are difficult to treat, aiming to enable clinicians to target undruggable disease targets with novel therapies that offer potentially life-changing efficacy.
Relation Therapeutics
Seed Round in 2022
Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.
Anagenex
Series A in 2022
Anagenex is a biotechnology company developing a novel platform for drug discovery. This platform focuses on challenging targets by combining machine learning with DNA-encoded libraries and proprietary AI models to accelerate small molecule drug discovery.
Ultima Genomics
Venture Round in 2022
Ultima Genomics is a biotechnology company established in 2016 and headquartered in Newark, California. It specializes in genome-scale sequencing technology, focusing on providing analytical services to various enterprises. By employing an open substrate, Ultima Genomics creates a vast, low-cost reaction surface that facilitates billions of reads without relying on expensive flow cells or complex fluidic systems. The company utilizes specialized sequencing hardware combined with machine learning techniques to ensure reproducible and accurate results. This innovative approach enables clients to obtain genomic reports at scale, enhancing the speed and efficiency of sequencing while significantly reducing costs. Ultima Genomics aims to harness the potential of genomic information to drive advancements in biology and improve human health.
Oobli
Series B in 2022
Oobli develops healthy, low-calorie protein sweeteners derived from exotic plants. These rare compounds offer great taste without affecting blood sugar levels or gut microbiome. The company has secured regulatory approvals such as FDA 'no questions' letters and GRAS status for multiple proteins.
Mirvie
Series B in 2022
Mirvie is a biotechnology company specializing in precise, non-invasive diagnostic tests for maternal-fetal health. Founded in 2018, the company aims to enhance pregnancy safety by providing actionable insights to families and enabling early intervention for potential complications.
VitroLabs
Series A in 2022
VitroLabs specializes in 3D tissue engineering, focusing on the development of real leather using stem cell-based technologies. Founded in 2016 and based in San Jose, California, the company aims to create luxury quality lab-grown leather with a low carbon footprint, thereby reducing harm to animals.
Turn.bio
Venture Round in 2022
Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing its patented mRNA platform technology ERA, the company targets indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.
Volta Labs
Series A in 2022
Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in engineering and developing innovative tools for biological automation, focusing on scalable automation solutions for genetic engineering. Its platform is designed to revolutionize genomics research by providing affordable genomic sample preparation and automation for complex biological workflows. By integrating expertise from engineering, surface chemistry, and molecular biology, Volta Labs aims to streamline sample processing and enhance the capabilities of biotech organizations in the next generation of genomic automation.
Scipher Medicine
Series D in 2022
Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.
Cellino
Series A in 2022
Cellino develops scalable, automated biomanufacturing systems for personalized cell therapies based on induced pluripotent stem cells (iPSCs). The company aims to enable potentially curative, patient-specific treatments by producing autologous iPSCs at scale and applying AI-guided, image-driven laser processing and robotics to remove unwanted cells. By integrating image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to enhance precision, efficiency, and scalability in optical bioprocessing, accelerating the development of regenerative therapies for chronic degenerative diseases such as vision loss and Parkinson's disease.
Faeth Therapeutics
Seed Round in 2022
Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.
Anagenex
Seed Round in 2022
Anagenex is a biotechnology company developing a novel platform for drug discovery. This platform focuses on challenging targets by combining machine learning with DNA-encoded libraries and proprietary AI models to accelerate small molecule drug discovery.
Prellis Biologics
Series B in 2021
Prellis Biologics is a biotechnology company based in San Francisco, founded in 2016, focused on bioprinting vascularized human tissues and organs for drug development, disease modeling, and transplantation. Its platform enables rapid, high-resolution printing of tissues and organoids, including lymph node models, to reproduce human immune responses. This capability supports antibody discovery, immunogenicity assessment, and tumor–immune studies, aiming to accelerate early-stage drug discovery and translational pharmacology while advancing the development of tissue and organ therapies.
NextVivo
Seed Round in 2021
NextVivo is a biotechnology company developing an immune organoid technology platform. This platform aims to transform drug development by accelerating the creation of safer, more effective therapies. It achieves this by generating and testing therapies in human-derived models that mimic the body's natural immune response.
Nabla Bio
Seed Round in 2021
Nabla Bio is a biotechnology company that uses artificial intelligence and lab technologies to rationally design novel proteins for drug development. They aim to create medicines and improve nutrition by engineering proteins with enhanced qualities.
Fountain Therapeutics
Series A in 2021
Founded in 2018, Fountain Therapeutics develops cellular model-based therapeutics targeting age-related diseases. It employs an AI-driven platform for identifying novel targets and potential treatments.
Viome Life Sciences
Series C in 2021
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Vertical Oceans
Seed Round in 2021
Vertical Oceans specializes in sustainable aquaculture, producing same-day farm-to-fork shrimp using vertical towers in urban markets. Their innovative system, the Intelligent Habitat (iHAB), combines bioengineering, hardware engineering, and computational methods to create a self-sustaining, self-cleaning modular production environment. This results in high-quality shrimp with excellent sustainability credentials.
Supplant
Series A in 2021
Supplant is a biotechnology platform working in the food sector. It develops natural food ingredients from agricultural resources to allow food manufacturers to decrease sugar, increase fiber, and boost the gut health-promoting qualities of its products.
Pearl Bio
Seed Round in 2021
Pearl Bio is a synthetic biology company that leverages its proprietary platform to create novel biologics and biomaterials. By engineering genomes and ribosomes, the company enables scientists to explore diverse chemistries and advance treatments for genetic or acquired diseases.
VitroLabs
Series A in 2021
VitroLabs specializes in 3D tissue engineering, focusing on the development of real leather using stem cell-based technologies. Founded in 2016 and based in San Jose, California, the company aims to create luxury quality lab-grown leather with a low carbon footprint, thereby reducing harm to animals.
Loyal
Series A in 2021
Loyal is a biotechnology company focused on developing medicines to extend the lifespan of dogs. By creating drugs that potentially slow aging processes, they aim to delay or prevent age-related diseases such as cancer and dementia.
Karma Biotechnologies
Seed Round in 2021
Founded in 2019, Karma Biotechnologies is a Los Angeles-based company dedicated to developing therapies for autoimmune diseases, allergies, and food sensitivities. It specializes in antigen-specific immunotherapies using lipid nanoparticle engineering.
Known Medicine
Seed Round in 2021
Known Medicine Inc. is a biotechnology company based in Salt Lake City, Utah, founded in 2020. The company specializes in developing a custom organoid platform designed for tumor sensitivity testing through advanced bioengineering techniques. Known Medicine focuses on transforming the process of evaluating how tumors respond to cancer therapies by taking tumor samples and breaking them down into microtumors. These microtumors are treated in specialized micro-environments using various methods to ascertain the most effective treatment options. The company's platform integrates machine learning with omics data to identify predictive biomarkers that inform oncologists about cancer cell behavior and potential treatment pathways, ultimately aiming to enhance personalized cancer care.
Encellin
Seed Round in 2021
Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.
Deep Genomics
Series C in 2021
Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.
IgGenix
Series A in 2021
IgGenix is a biotechnology company that develops an antibody-based therapeutic platform to treat food and other severe allergies. The platform re-engineers allergen-specific IgE antibodies into IgG antibodies to suppress the allergic cascade and alleviate or prevent allergic reactions. It identifies rare human B cells expressing allergen-binding antibodies and engineers them to endow immune-modulating activities derived from the IgG antibody class. Based in South San Francisco, California, the company aims to accelerate clinical responses to life-threatening allergies.
Ochre Bio
Seed Round in 2021
Ochre Bio is a biotechnology company founded in 2019 and headquartered in Oxford, United Kingdom. The firm focuses on developing genomic medicines that rejuvenate donor livers before transplantation, aiming to expand the supply of healthy organs for patients. By using genomics to identify and silence over‑active genes that drive liver disease, Ochre Bio tests novel RNA‑based therapies directly in discarded donor livers maintained on machine‑based perfusion systems. This approach allows the company to evaluate treatments in a human organ context, reducing complications such as cirrhosis and improving transplant outcomes. With more than fifteen years of liver genomics research experience, Ochre Bio leverages deep phenotyping and advanced therapeutic modalities to create a pipeline of medicines for liver and liver‑mediated conditions.
Synchron
Series B in 2021
Synchron is a company that develops implantable neural interfaces designed to restore motor function by recording and interpreting brain activity through minimally invasive devices. Its catheter-delivered brain implants record neuron signals and translate them into control signals for prosthetics or digital devices, enabling users with motor impairments to interact with technology through thought. The devices incorporate electrode arrays within a stent-like platform to create a brain-computer interface that modulates neural activity in targeted brain regions. The goal is to provide a less invasive option for patients to regain voluntary control over assistive technologies, augmenting mobility and communication for those with paralysis or severe motor limitation.
Clear Labs
Series C in 2021
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Overture Life
Series B in 2021
Overture Life, Inc. is a biotechnology company based in New York, established in 2017, that specializes in developing robotic solutions for in vitro fertilization (IVF) applications. The company focuses on automating the IVF process through innovative medical devices and embryo testing methodologies, which enhance the efficiency and success rates of fertility treatments. By optimizing resource use and lowering costs, Overture Life aims to make IVF more accessible to a broader audience. Its technology includes automated cryopreservation and embryo testing services, enabling fertility clinics to identify viable embryos prior to implantation, thereby improving patient outcomes and supporting individuals in their journey to parenthood.
Apton Biosystems
Series A in 2021
Apton Biosystems, Inc. is a biotechnology company based in Pleasanton, California, founded in 2012. The company specializes in developing advanced optical systems for sequencing and protein detection, utilizing super-resolution technology to analyze molecules that are spaced closer than the wavelength of light. This innovative approach facilitates multi-omic sequencing and single-molecule protein detection, significantly enhancing capabilities in biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems aims to advance preventive health and precision medicine by addressing spatial challenges in high-density sequencing and protein analysis, thus contributing to improved healthcare outcomes.
Turn.bio
Funding Round in 2021
Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing its patented mRNA platform technology ERA, the company targets indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.
Pendulum Therapeutics
Series C in 2021
Pendulum Therapeutics is a biotechnology company specializing in microbiome-targeted therapies. Founded in 2013 by experts in microbiology, biochemistry, computational science, and clinical research, the company develops evidence-based medical probiotics to manage chronic illnesses, with a focus on type 2 diabetes. Its flagship product, Pendulum Glucose Control, has demonstrated efficacy in lowering blood sugar spikes and reducing A1C levels in clinical trials.
Scipher Medicine
Series C in 2021
Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.
Briefcase Biotec
Seed Round in 2021
Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours.
KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development.
Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.
Inflammatix
Series D in 2021
Inflammatix develops rapid molecular diagnostics tests that interpret the immune system to resolve major clinical challenges. Initially focused on acute bacterial and viral infections, sepsis, and other conditions like tropical infections and autoimmune diseases.
Bionaut Labs
Series A in 2021
Founded in 2016, Bionaut Labs specializes in developing intra-tissue navigation platforms using micro-robots for precise anatomical targeting. Its innovative technology enables remote-controlled delivery of therapeutics to challenging clinical settings, revolutionizing the treatment of central nervous system disorders and other diseases.
Egenesis
Series C in 2021
Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.
Supplant
Series A in 2021
Supplant is a biotechnology platform working in the food sector. It develops natural food ingredients from agricultural resources to allow food manufacturers to decrease sugar, increase fiber, and boost the gut health-promoting qualities of its products.
Cellino
Seed Round in 2021
Cellino develops scalable, automated biomanufacturing systems for personalized cell therapies based on induced pluripotent stem cells (iPSCs). The company aims to enable potentially curative, patient-specific treatments by producing autologous iPSCs at scale and applying AI-guided, image-driven laser processing and robotics to remove unwanted cells. By integrating image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to enhance precision, efficiency, and scalability in optical bioprocessing, accelerating the development of regenerative therapies for chronic degenerative diseases such as vision loss and Parkinson's disease.
Ukko
Series B in 2021
Ukko is a biotechnology company focused on enhancing the quality of life for individuals affected by food allergies and disorders. The company utilizes a computational engineering platform that employs artificial intelligence, immunology, and protein engineering to redesign food allergens into therapeutics that are both safe and effective. By creating a comprehensive, clinically validated map of the molecular structures associated with food allergies, Ukko reveals critical insights into the biological mechanisms governing human-food interactions. This innovative approach enables the development of new protein versions that do not provoke an immune response, providing a novel strategy for treating protein-based allergies.
Earli
Series A in 2021
Earli is a biotechnology company focused on advancing cancer detection and treatment through innovative technology. The company specializes in developing devices that utilize a novel gene therapy approach known as Synthetic Biopsy. This method compels cancer cells to produce synthetic biomarkers, which are not naturally occurring in the human body. These biomarkers can then be detected in bodily fluids such as blood, urine, or breath, allowing for early identification of cancer. By facilitating the early detection of homogeneous tumors, Earli aims to significantly improve the chances of successful treatment and personalize therapy options for patients. Additionally, the technology is designed to be visible during imaging procedures such as PET scans, enhancing the monitoring of cancer progression and treatment efficacy.
Rubedo Life Sciences
Seed Round in 2020
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.
Advanced Chemotherapy Technologies
Series A in 2020
Advanced Chemotherapy Technologies is a healthcare company that is developing breakthrough combination drug-device technologies for treating pancreatic cancer.
Siolta Therapeutics
Series B in 2020
Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.
Invoy
Series A in 2020
Invoy is a company focused on enhancing health and weight loss outcomes through the integration of science, data, and artificial intelligence. It develops a monitoring medical device that offers personalized nutrition and wellness services by generating real-time data on an individual's metabolism. This device not only provides tailored, predictive nutrition recommendations but also features affordable breath analyzers for medical applications. By addressing the unique body chemistry of each individual, Invoy aims to empower users to achieve their specific health and wellness objectives.
SiPhox Health
Seed Round in 2020
SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.
IgGenix
Series A in 2020
IgGenix is a biotechnology company that develops an antibody-based therapeutic platform to treat food and other severe allergies. The platform re-engineers allergen-specific IgE antibodies into IgG antibodies to suppress the allergic cascade and alleviate or prevent allergic reactions. It identifies rare human B cells expressing allergen-binding antibodies and engineers them to endow immune-modulating activities derived from the IgG antibody class. Based in South San Francisco, California, the company aims to accelerate clinical responses to life-threatening allergies.
Oobli
Series A in 2020
Oobli develops healthy, low-calorie protein sweeteners derived from exotic plants. These rare compounds offer great taste without affecting blood sugar levels or gut microbiome. The company has secured regulatory approvals such as FDA 'no questions' letters and GRAS status for multiple proteins.
Menten AI
Seed Round in 2020
Menten AI, established in 2018 with headquarters in San Francisco and a satellite office in Toronto, is an early-stage biotech company specializing in drug discovery. It leverages machine learning and quantum computing to develop novel protein-based drugs and enzymes for pharmaceutical and chemical industries. Menten AI's core offering is a proprietary protein design algorithm tailored for current and near-term quantum computers, enabling efficient exploration of protein structures for therapeutic applications, such as oncology and neurodegeneration, and industrial enzyme development.
Clear Labs
Venture Round in 2020
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Genalyte
Series C in 2020
Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.
E25Bio
Venture Round in 2020
E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018, that focuses on developing rapid diagnostic tests for epidemic fever viruses. The company designs paper-based diagnostic systems and kits that facilitate the detection of viruses such as dengue, chikungunya, and Zika. E25Bio's innovative platform enables multiplexed testing that quickly identifies viral antigens during infections, allowing for real-time data reporting through a mobile application. This capability supports epidemiologic predictions and disease mapping, empowering governments and health organizations to respond effectively to outbreaks and manage public health crises. Through its commitment to fast, mobile testing solutions, E25Bio aims to prevent severe health outcomes associated with viral epidemics.
Karius
Series B in 2020
Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.